Pfizer inks EU shot supply deal To view this email as a web page,
click here Pfizer's COVID-19 vaccine looks impressive, but Sanofi, J&J and Novavax shots eye a logistics edge Pfizer, BioNTech ink multibillion-dollar EU deal for up to 300M doses of COVID-19 vaccine Healthcare roundup: Medicare to cover new antibody cocktail Does that PPE meet safety standards? Report finds many disposable gowns don't Amid cold chain blues, Pfizer looks to powder vaccine formula in 2021: report Lucky Pfizer CEO Bourla cashes out $5.6M worth of stock—perfectly legally—as COVID vaccine data lifts market Qiagen joins with T-cell biotech TScan to develop immune system test for COVID-19 Pent-up demand, return-to-work market boosts One Medical's membership Featured Story | By Eric Sagonowsky Pfizer's COVID-19 vaccine this week set high efficacy expectations, but the vaccine has stringent storage needs and requires two doses, creating significant challenges for a massive vaccination campaign. If they prove themselves in the clinic, later-arriving shots from the likes of Sanofi, J&J and Novavax may be better suited for global distribution. read more |
| |
|---|
|
Top Stories By Kyle Blankenship With interim results out of the way, Pfizer and BioNTech are looking to speed their COVID-19 vaccine ahead to a regulatory approval in the coming weeks and into high-risk patients' arms. Now, thanks to a multibillion-dollarsupply deal with the European Commission, the road is clear for a rollout on the continent. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Robert King More than 50% of isolation gowns from foreign and nontraditional suppliers didn't meet key standards used to weigh whether the gowns protect healthcare workers, an analysis from ECRI found. read more By Fraiser Kansteiner Promising news Monday on the efficacy of Pfizer and BioNTech's vaccine candidate was met with concerns over access given the shot's stringent cold chain storage requirements. But the drugmaker is already weighing a solution in the form of a powder formulation that would likely only require standard refrigeration, the company's top scientist said. read more By Arlene Weintraub On Monday, the same day that Pfizer announced that its COVID-19 vaccine was 90% effective in a clinical trial, CEO Albert Bourla sold 132,508 shares in a transaction that was set up months ago. It was the latest stroke of good fortune for a CEO who has already seen his pay skyrocket on R&D successes. read more By Conor Hale Qiagen has begun working with a biotech startup focused on cell therapies to develop a COVID-19 diagnostic test capable of comprehensively profiling a person’s immune response to the disease. read more By Heather Landi Pent-up demand for healthcare services and the return-to-work market among employers helped boost One Medical's third-quarter revenue to $102 million, up 46% from $70 million during the same period last year. Here's how much the primary care company's membership grew during the third quarter. read more |
|
